Zobrazeno 1 - 10
of 298
pro vyhledávání: '"Russel, Burge"'
Autor:
Paul Klekotka, Louis Lavoie, Beth Mitchell, Ike Iheanacho, Russel Burge, Andrea Cohee, Joanne Puckett, Ajay Nirula
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionSeveral current therapies for autoimmune diseases do not provide sustained remission. Therapies that focus on the restoration of homeostasis within the immune system (i.e., immune resolution) could overcome the limitations of current ther
Externí odkaz:
https://doaj.org/article/4365c4d5d25c46fdb6aac5bf7520a9c3
Autor:
Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 1007-1018 (2024)
Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat wit
Externí odkaz:
https://doaj.org/article/2172459873774bdcb1e836294768df9a
Autor:
Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1831-1846 (2023)
Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s pers
Externí odkaz:
https://doaj.org/article/114f099f9c514b8f96ecb4ac00b347b4
Autor:
Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 2, Pp 282-292 (2023)
Abstract Background People with genital psoriasis may avoid close social interactions (hugs, handshakes, kisses, touching others, or being touched), which can have a significant impact on quality of life. Ixekizumab, an interleukin 17A antagonist, de
Externí odkaz:
https://doaj.org/article/ffcd1adcd24c46c0986747258116f460
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 6, Pp 1397-1404 (2020)
Abstract Introduction Ixekizumab has demonstrated rapid onset of action, high levels of skin clearance, and improvements in quality of life in patients with moderate-to-severe psoriasis, including plaque, erythrodermic, or generalized pustular psoria
Externí odkaz:
https://doaj.org/article/22fbc0054777457194be6b7549b4bf76
Autor:
Craig Leonardi, Kristian Reich, Peter Foley, Hideshi Torii, Sascha Gerdes, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Christopher E. M. Griffiths, Hany ElMaraghy, Heidi Crane, Himanshu Patel, Russel Burge, Gaia Gallo, David Shrom, Ann Leung, Chen-Yen Lin, Kim Papp
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 3, Pp 431-447 (2020)
Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety of ixeki
Externí odkaz:
https://doaj.org/article/9fcdd75b0c314187bca955c0a6fd2339
Autor:
Alexander Egeberg, Yuki M F Andersen, Amy M DeLozier, Lea Nymand, Russel Burge, Emily Edson-Heredia
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/6ee1a37846c0495696817a5059056c16
Autor:
Richard B. Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 1, Pp 73-86 (2019)
Abstract Introduction Rapid improvement of psoriasis is valued by patients and should be considered to be an important factor in treatment selection. We investigated Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) r
Externí odkaz:
https://doaj.org/article/c8ae023d46de403a8372108d4bebb25b
Autor:
Joe Gorelick, David Shrom, Kiran Sikand, Lisa Renda, Russel Burge, Christine Dworkin, Craig Krebsbach, Ripsi P. Patel, Chitra Karki, David Rosmarin
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 4, Pp 785-797 (2019)
Abstract Introduction The goal of psoriasis (PsO) treatment is to improve quality of life by lessening the extent and severity of the disease. Traditional systemic drugs and biologic agents are used for the treatment of moderate to severe PsO and rec
Externí odkaz:
https://doaj.org/article/ee4d436bde94463aa7e4e0364d9c80c0
Autor:
Pieralessandro Lasalvia, Yaneth Gil-Rojas, Emmanuel Papadimitropoulos, Russel Burge, Diego Rosselli
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 23:511-517
Psoriasis is a chronic systemic inflammatory disease manifesting as erythematous and desquamative dermatoses. This study estimated the cost per responder (CPR) for the treatment of moderate-to-severe plaque psoriasis with biologic therapies approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09f14d2b0b5fb2f110186158c64ae746
https://doi.org/10.1080/14737167.2023.2190514
https://doi.org/10.1080/14737167.2023.2190514